Rasagiline Mesylate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

甲磺酸雷沙吉兰是一种新型 MAO-B 抑制剂，用于治疗特发性帕金森病。

Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.(In Vitro):Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.(In Vivo):Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.

Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.Cell Viability Assay Cell Line:Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG Concentration:0.25 nM Incubation Time:96 hours Result:Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy. Animal Model:(PLP)-α-synuclein transgenic mice over 6 months of age Dosage:Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.) Administration:Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment). Result:Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.

——

Metabolic Enzyme/Protease

MAO

MAO-A| MAO-B

Neurological Disease

——

161735-79-1

267.34

C13H17NO3S

>98% (HPLC)

Soluble in water

CS(=O)(=O)O.C#CCN[C@@H]1CCC2=CC=CC=C12

——

(-20℃)

With Ice Pack

≥ 2 years